Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 2/20 | 0.42 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | PKLR | P30613 | 4/20 | 0.41 |
| ▸ | FPR2 | P25090 | 3/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126115 | 0.95 | EPHX2 (0.43) | EPHX2ACLYCYP46A1CNR1PKLR | |
| SCHEMBL3828231 | 0.88 | CCR1 (0.46) | EPHX2ACLYCNR1 | |
| SCHEMBL5121390 | 0.88 | PKLR (0.49) | EPHX2CYP46A1PKLRTACR1ALDH1A1 | |
| SCHEMBL5131185 | 0.87 | ACLY (0.45) | EPHX2ACLYCYP46A1CNR1PKLR | |
| SCHEMBL5131355 | 0.86 | AVPR1A (0.46) | CYP46A1PKLRALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL5132135 | 0.83 | CCR1 (0.51) | CNR1ALDH1A1 | |
| SCHEMBL5125142 | 0.82 | AVPR1A (0.48) | ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL5128879 | 0.82 | GAA (0.49) | CYP46A1GRIN2BALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL5131447 | 0.82 | PKM (0.46) | CYP46A1PKLRGRIN2BALDH1A1PKM | |
| SCHEMBL5131253 | 0.82 | CNR1 (0.40) | ACLYCNR1ALDH1A1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086935-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2009-08-12 | — | — | EP | claimed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| WO-2008046573-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES FOR USE AS BRADYKININ 1 RECEPTOR MODULATORS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | EPHX2 1287/4885ACLY 4105/4885CYP46A1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.